4000003663 nieuw aanvraagnummer ivm conversie - DSO - Fonds voor PDP's III DSO   Fonds voor Product Development Partnerships (PDPs) III With the Product Development Partnerships III Fund (2015-2021) the Dutch Ministry of Foreign Affairs made EUR 86.3 million available for six Product Development Partnerships (PDPs): not-for-profit public-private partnerships for research and development of medicines, vaccines, diagnostics and other products to promote sexual and reproductive health, prevent and combat poverty-related diseases and conditions, and prevent and combat new and recurring epidemics in low- and middle-income countries. In 2020, the grant period was extended by one year with an extra amount of EUR 17.3 million. In 2021, PDP III was externally evaluated. The researchers found that the 6 PDPs made substantial progress in terms of product pipeline development. Since the start of PDP III, 375 new products were in the product pipeline and between 2015 and 2021, 30 products moved one phase in the development process. Twelve products have reached marketing stage and have been registered with national authorities or international organizations such as the World Health Organization. These twelve products are: fexinidazole for the treatment of sleeping sickness (DNDi); TB Ultra Test, Xpert XDR and Omni for the diagnosis of tuberculosis; ProBio and Standard Q for the diagnosis of COVID-19 (FIND); The Dapivirine Vaginal Ring to reduce the risk of HIV infection (IPM); pyronaride-artesunate (Pyramax(R)) tablets and paediatric granules, artesunate rectocaps and tafenoquine for the treatment of various forms of malaria (MMV); and pretomanid as part of treatment for multidrug-resistant tuberculosis (TB Alliance).